Cytonus Therapeutics is pioneering a novel approach to drug delivery through its innovative Cargocyte™ platform, which integrates artificial intelligence (AI) with synthetic biology. This technology aims to enhance the efficacy and safety of therapeutics by enabling precise targeting of disease sites, particularly in challenging areas such as tumors and fibrotic tissues. The Cargocytes are engineered to be enucleated synthetic cells that can deliver and produce biologic drugs directly at the site of disease, thereby minimizing systemic exposure and associated toxicities. This targeted delivery mechanism is designed to address the high failure rates of traditional drug development, which often do not account for the complexities of human biology.

The Cargocyte platform leverages proprietary AI tools to facilitate rapid screening and testing of new therapeutics, allowing for the creation of best-in-class treatments tailored to specific clinical applications. These synthetic entities are designed to be allogeneic, meaning they can be administered to any patient, and can be produced at scale for off-the-shelf availability. By focusing on both the design and delivery of therapeutics, Cytonus aims to shift the paradigm of patient treatment, ensuring that drugs are not only effective but also delivered safely and efficiently to the intended sites of action.

United States

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

Cytonus Therapeutics

Company Details